Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA), Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany), and Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, USA) discuss all the important prostate cancer studies from ASCO GU 2022.
The three experts roundup key data and give their analysis and commentary on potential clinical impact.
Prof Merseburger talks about the overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
Prof Merseburger and Prof Efstathiou also talk about the phhase III PROpEL trial of olaparib and abiraterone versus placebo and abiraterone as first-line (1L) therapy for patients with metastatic castration-resistant prostate cancer.
The panel also comments on the PRESIDE and MAGNITUDE studies. They conclude by discussing what the impact of these results can be in the clinic and what does the future look like for the treatment of prostate cancer.